Burkitt's lymphoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2], Kamal Akbar, M.D.[3]

Overview

The predominant therapy for Burkitt’s lymphoma is chemotherapy. Adjunctive immunotherapy and stem cell transplantation may be required.

Medical Therapy

The predominant therapy for Burkitt’s lymphoma is chemotherapy. Adjunctive immunotherapy and stem cell transplantation may be required.^[1]

Chemotherapy

Chemotherapeutic regimens for Burkitt’s lymphoma include:^[2]
Cyclophosphamide AND Vincristine AND Doxorubicin AND Methotrexate (CODOX-M)^[3]^[4]
Ifosfamide AND Mesna AND Etoposide AND Cytarabine (IVAC)^[5]^[4]
Cyclophosphamide AND Vincristine AND Doxorubicin AND Dexamethasone AND Methotrexate AND Cytarabine (Hyper-CVAD)^[6]

CNS prophylaxis

There is a high risk that Burkitt’s lymphoma will spread to the central nervous system (CNS)
CNS prophylaxis may involve giving intrathecal chemotherapy, high doses of systemic therapy, or both methods may be used^[7]
Methotrexate and Cytarabine are the drugs used most often for CNS prophylaxis^[8]

Biological therapy

Monoclonal antibodies are a type of biological therapy that is effective in treating Burkitt’s lymphoma^[9]
Rituximab may be added to each of the above chemotherapy regimens^[2]^[6]

Stem cell transplant

A stem cell transplant may be offered to patients with recurrent Burkitt’s lymphoma or to patients who relapse after the treatment.^[2]

References

↑ Burkitt lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/burkitt-lymphoma/?region=on Accessed on September 28, 2015
↑ ^2.0 ^2.1 ^2.2 Jacobson, C.; LaCasce, A. (2014). “How I treat Burkitt lymphoma in adults”. Blood. 124 (19): 2913–2920. doi:10.1182/blood-2014-06-538504. ISSN 0006-4971.
↑ Zhu KY, Song KW, Connors JM, Leitch H, Barnett MJ, Ramadan K; et al. (2018). “Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab”. Br J Haematol. 181 (6): 782–790. doi:10.1111/bjh.15262. PMID 29741758.
↑ ^4.0 ^4.1 Noy A, Lee JY, Cesarman E, Ambinder R, Baiocchi R, Reid E; et al. (2015). “AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma”. Blood. 126 (2): 160–6. doi:10.1182/blood-2015-01-623900. PMC 4497960. PMID 25957391.
↑ Bortz, H.; Coutsouvelis, J.; Corallo, C. E.; Spencer, A.; Patil, S. (2015). “Modifying chemotherapeutic management of a patient with Burkitt’s lymphoma and pre-existing motor neurone disease”. Journal of Clinical Pharmacy and Therapeutics. 40 (4): 483–485. doi:10.1111/jcpt.12293. ISSN 0269-4727.
↑ ^6.0 ^6.1 Thomas DA, O’Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W; et al. (2010). “Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia”. J Clin Oncol. 28 (24): 3880–9. doi:10.1200/JCO.2009.26.9456. PMC 2940403. PMID 20660823.
↑ González-Barca E, Canales M, Salar A, Ferreiro-Martínez JJ, Ferrer-Bordes S, García-Marco JA; et al. (2016). “Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial”. Ann Hematol. 95 (6): 893–9. doi:10.1007/s00277-016-2648-4. PMC 4853453. PMID 27025508.
↑ Peñalver FJ, Sancho JM, de la Fuente A, Olave MT, Martín A, Panizo C; et al. (2017). “Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO)”. Haematologica. 102 (2): 235–245. doi:10.3324/haematol.2016.149120. PMC 5286932. PMID 27846613.
↑ Wiels J, Fellous M, Tursz T (1981). “Monoclonal antibody against a Burkitt lymphoma-associated antigen”. Proc Natl Acad Sci U S A. 78 (10): 6485–8. PMC 349064. PMID 7031655.

Template:Chromosomal abnormalities

Template:WikiDoc Sources

[Cancer.ca-1] Burkitt lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/burkitt-lymphoma/?region=on Accessed on September 28, 2015

[JacobsonLaCasce2014-2] 2.0 ^2.1 ^2.2 Jacobson, C.; LaCasce, A. (2014). “How I treat Burkitt lymphoma in adults”. Blood. 124 (19): 2913–2920. doi:10.1182/blood-2014-06-538504. ISSN 0006-4971.

[pmid29741758-3] Zhu KY, Song KW, Connors JM, Leitch H, Barnett MJ, Ramadan K; et al. (2018). “Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab”. Br J Haematol. 181 (6): 782–790. doi:10.1111/bjh.15262. PMID 29741758.

[pmid25957391-4] 4.0 ^4.1 Noy A, Lee JY, Cesarman E, Ambinder R, Baiocchi R, Reid E; et al. (2015). “AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma”. Blood. 126 (2): 160–6. doi:10.1182/blood-2015-01-623900. PMC 4497960. PMID 25957391.

[BortzCoutsouvelis2015-5] Bortz, H.; Coutsouvelis, J.; Corallo, C. E.; Spencer, A.; Patil, S. (2015). “Modifying chemotherapeutic management of a patient with Burkitt’s lymphoma and pre-existing motor neurone disease”. Journal of Clinical Pharmacy and Therapeutics. 40 (4): 483–485. doi:10.1111/jcpt.12293. ISSN 0269-4727.

[pmid20660823-6] 6.0 ^6.1 Thomas DA, O’Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W; et al. (2010). “Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia”. J Clin Oncol. 28 (24): 3880–9. doi:10.1200/JCO.2009.26.9456. PMC 2940403. PMID 20660823.

[pmid27025508-7] González-Barca E, Canales M, Salar A, Ferreiro-Martínez JJ, Ferrer-Bordes S, García-Marco JA; et al. (2016). “Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial”. Ann Hematol. 95 (6): 893–9. doi:10.1007/s00277-016-2648-4. PMC 4853453. PMID 27025508.

[pmid27846613-8] Peñalver FJ, Sancho JM, de la Fuente A, Olave MT, Martín A, Panizo C; et al. (2017). “Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO)”. Haematologica. 102 (2): 235–245. doi:10.3324/haematol.2016.149120. PMC 5286932. PMID 27846613.

[pmid7031655-9] Wiels J, Fellous M, Tursz T (1981). “Monoclonal antibody against a Burkitt lymphoma-associated antigen”. Proc Natl Acad Sci U S A. 78 (10): 6485–8. PMC 349064. PMID 7031655.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]